Allogene Therapeutics, Inc.
Most recent annual filing: 2026-03-15
Pipeline (12 active programs)
ALLO-316
ALLO-329
- Systemic Lupus Erythematosus
- Idiopathic Inflammatory Myopathies
- Systemic Sclerosis
- Undisclosed indication
ALLO-715
ALLO-819
ALLO-213
ALLO-182
Cell Target: Claudin 18.2
ALLO-647
- Undisclosed indication
Technology platforms
Dagger
Anti-CD70 CAR-based technology incorporated into allogeneic CAR T cell products to eliminate CD70-expressing activated host T cells and alloreactive lymphocytes, enabling a window of CAR T cell persistence. Used in oncology (ALLO-316) and autoimmune disease (ALLO-329) programs to reduce or eliminate lymphodepletion requirements.
Targets: CD70, BCMA
Discontinued (1)
- ALLO-647 — undisclosed · terminated further development of ALLO-647 following Grade 5 treatment-related serious adverse event
Biotech Distilled coverage (3)
- 2026-05-14 UPDATE: Allogene Therapeutics (ALLO) - The IP Sword Gets a Second Edge 🔒 Paid
- 2026-04-27 UPDATE: Allogene Therapeutics (ALLO) - The Data Hit, The Raise Stung 🔒 Paid
- 2026-03-27 Allogene Therapeutics (ALLO) - Scientific Deep Dive for Lead and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.